43results about How to "Specific targeting" patented technology

The invention relates to methods of targeted drug delivery of compounds, including, chemical agents, (poly)peptides and nucleic acid based drugs (like DNA vaccines, antisense oligonucleotides, ribozymes, catalytic DNA (DNAzymes) or RNA molecules, siRNAs or plasmids encoding thereof). Furthermore, the invention relates to targeted drug delivery of compounds to extravascular and intracellular target sites within cells, tissues and organs, in particular to target sites within the central nervous system (CNS), into and across the blood-brain barrier, by targeting to glutathione transporters present on these cells, tissues and organs. Thereto, the compounds, or the pharmaceutical acceptable carrier thereof, are conjugated to glutathione-based ligands that facilitate the specific binding to and internalization by these glutathione transporters.

The invention provides an active targeting type amphipathic polypeptide nano-drug carrier and preparation and application thereof, and belongs to the technical field of biological medicines. According to an amphipathic polypeptide, an alkyl chain serves as the hydrophobic end, a polypeptide chain with active targeting functional and side chain modification fluorescent functional molecules serves as the hydrophilic end, and an anti-tumor drug is wrapped in a hydrophobic cavity of a micelle formed by self-assembling the amphipathic polypeptide. The nano-carrier can actively target tumor cells and enter the tumor cells through receptor-mediated endocytosis, the amphipathic polypeptide and phospholipid molecules have strong interaction, and the phagocytosis of a nano-drug by tumor cells is promoted. In the process, tracing can be conducted through fluorescent imaging of fluorescent functional molecules modified on the polypeptide chain, and the tumor imaging aim is realized. Finally, the anti-tumor drug is slowly released to kill tumor cells and restrain the growth of tumors. The amphipathic polypeptide nano-carrier is free of toxin, high in biocompatibility and remarkable in anti-tumor efficiency, and the tumor diagnosis and treatment can be integrated.

An antigen derived from an intracellular pathogenic micro-organism characterized in that it comprises at least on peptidic fragment which essentially consists of the concatenation of sequences of at least two extracellular adjacent areas in the native structure of a membrane protein of type III of said intracellular pathogenic micro-organism, derived conformational antibodies and the application hereof.

Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.

The movement of animals may be controlled by recording a sound which initiates movement in an animal and combining that movement initiating sound with additional sounds to produce music. A preferred embodiment uses the sound of one or more active dragonflies in combination with at least one of instrumental notes and sounds of nature to repel mosquitoes, flies and other closely related insects while attracting or entertaining humans.

The present invention discloses a novel anti-crop-epiphyte polypeptide and a preparation method thereof. A recombined anti-crop-epiphyte polypeptide is formed by linking gene which codes white candida pheromone and the gene which codes colicin. Compared with the prior anti-crop-epiphyte medicine, the novel anti-crop-epiphyte polypeptide of the present invention has the advantages that the novel anti-crop-epiphyte polypeptide directly forms ionic passage at epiphytic cell membrane to kill the epiphyte, so the killing efficiency is thousands times stronger than the prior anti-crop-epiphyte medicine; the epiphyte can hardly amend the geometrical damage at the cell membrane caused by the polypeptide by the mutation-expression form, so the polypeptide can not induce the epiphyte producing the traditional drug resistance; the polypeptide is a biological preparation and has target killing towards the epiphyte, so the novel anti-crop-epiphyte polypeptide does not have the toxic and side effects of the prior anti-crop-epiphyte medicine.

The invention belongs to the field of biological medicinal preparation and relates to a preparation technology and an application of a natural recombinant nanostructured lipid carrier. The specifically-refereed nanoparticle is natural recombinant lipoprotein drug-loaded nanoparticle and is prepared by in vitro recombination of an apolipoprotein mixture and lipid which are obtained by extraction and purification of a blood plasma ingredient IV and a medicament. The recombination process is realized by a film dispersion method, an emulsification-evaporation method or an emulsification-evaporation improved method. The technical problem to be solved in the invention is the extraction and purification method of apolipoprotein and lipid mixture and the preparation technology of the natural recombinant lipoprotein drug-loaded nanoparticle. Preparation conditions are mild, and costs are low. The natural recombinant lipoprotein nanoparticle provided by the invention has remarkable advantages of spheroidic structure, high bionic performance, high penetrability, efficient carrying performance, tumor targeting and the like. The invention provides property evaluation and application of the above natural recombinant lipoprotein nanoparticle. Normal saline, or a phosphate buffer or 5% glucose solution is added to dissolve the nanoparticle, and the dissolved nanoparticle can be used to treat diseases in a mode of intravenous injection, intramuscular injection, oral medication or cutaneous penetration. The technology provided by the invention is simple and low-cost and is easy for industrial production.

The invention relates to a hyaluronic acid-modified amide hectorite nanoparticle and a preparation and an application of the hyaluronic acid modified hectorite amide nanoparticle. The hyaluronic acid modified hectorite amide nanoparticle is (3-amino propyl) ethoxydimethylsilane modified hectorite; and the mass fraction of the hyaluronic acid in the nanoparticle is 17.17%-19.09%. The preparation method comprises the following steps: modifying a hectorite surface with (3-amino propyl) ethoxydimethylsilane on to obtain hectorite amide; and through covalent action of amino and carboxyl, grafting the hectorite amide surface with hyaluronic acid, thus obtaining the hyaluronic acid modified hectorite amide nanoparticle. The stability and the biocompatibility of the nanoparticle are improved; meanwhile, the hyaluronic acid-modified hectorite amide nanoparticle has specific targeting action on cancer cells with high expression for a CD44 receptor, and can be applied to targeted delivery of anti-cancer drugs; and the hyaluronic acid-modified hectorite amide nanoparticle is simple in preparation method, mild in reaction condition and easy to operate, and has an industrial implementation prospect.

The hHscFv gene sequences encode the plants. The synthetic DNA includes: the nucleic acid sequence which is 70% same to the 51-812bp nucleic acids of the SEQ IDNO.1 encodes the multi peptides with the hHscFv activity. The sequence encodes the multi peptides with the amino acid sequence of the SEQ ID NO.2. The peptides have the important value for curing the hepatocellular carcinoma.

The invention discloses an active targeting type amphiphilic polypeptide composite nano-micelle prodrug as well as preparation and application thereof, and belongs to the technical field of biological medicines. The composite nano-micelle prodrug is obtained by co-assembling a first polypeptide with negative charges and a second polypeptide with positive charges through electrostatic interaction and hydrophilic and hydrophobic effects; the first polypeptide is Lys-AAm-Gly-Arg-Gly-Asp-Ser, wherein AA is aspartic acid or glutamic acid, and m is 1, 2, 3 or 4; the second polypeptide is Cys-BBn, wherein BB is lysine, arginine or histidine, and n is 1, 2, 3 or 4; amino at a N end of the first polypeptide is connected with a hydrophobic alkyl chain, and amino at a lysine side chain of the first polypeptide is connected with a fluorescent molecule; cysteine in the second polypeptide is covalently linked with an anti-tumor drug through sulfydryl. The nano-composite micelle can be actively targeted to tumor cells, and is disassembled after responding to a tumor slightly acidic environment to form a small-size micelle with a size of 20-30 nm, so that deep delivery of the polypeptide anti-tumor prodrug at a tumor part is facilitated.

Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications.

The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3′,5 ‘-monophosphate analogues as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.

The invention discloses a biomimetic multifunctional lipoprotein nanoparticle modified by biological peptide and a preparation method and application thereof, the multifunctional biomimetic lipoprotein nanoparticle is composed of a biomimetic lipoprotein nano-carrier shell modified by biological peptide and a nano-form drug core, and the carrier shell is composed of apolipoprotein bionic peptide, biological peptide and natural phospholipid substitute. The preparation method comprises a film dispersion method and an emulsification evaporation method. The preparation method disclosed by the invention is simple and mild in condition and low in cost, and the prepared biological peptide modified biomimetic multifunctional lipoprotein nanoparticle has the advantages of high drug loading capacity, high biomimetic property, strong penetrability, biological safety, lesion site targeting property, drug loading mode diversity and the like. A nano-drug delivery platform can realize 'diagnosis and treatment integration' and 'multi-mode combined treatment', and can realize timely diagnosis and efficient treatment of complex progressive diseases such as tumors, neurodegenerative diseases and the like.

The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors.

The invention discloses a multi-response core-shell structure nanogel, and a preparation method and application thereof, and belongs to the technical field of gel preparation. The method specifically comprises the following steps: 1, preparing a nanogel aqueous solution by a reflux precipitation polymerization method; 2, coating the outer surface of the nanogel core with chitosan to obtain chitosan-coated nanogel; and 3, coating the outer surface of chitosan with a hyaluronic acid shell layer to obtain the core-shell mechanism nanogel. The nanogel core is coated with the chitosan and the hyaluronic acid, the nanogel with a core-shell structure is prepared, and the obtained nanogel has temperature/pH/reduction multiple stimulation responsiveness. The coated hyaluronic acid shell layer can be specifically combined with a CD44 receptor on the surface of cancer cells, so that the nanogel can specifically target tumor cells.

The invention discloses a fusion protein of a complement receptor 2 mutant and a complement inhibitor CD 59 and application thereof to preparing autoimmune disease treating drugs. The complement receptor 2 mutant is a molecular modified body obtained through computer modelling and amino acid replacement and is higher in ligand binding and dissociation rate and ligand binding force compared with wild sequences. Biological distribution test shows that the fusion protein can be highly concentrated at arthritic parts after entering mouse models with rheumatoid arthritis and achieve significant anti-adhesion/anti-inflammatory targeted inhibition effects; when applied to treating MRL/lpr (Murphy Roths large/lymphoproliferation) mice with systemic lupus erythematosus, the fusion protein can significantly improve the survival rate of the mice, and symptoms of the mice of a treatment group such as proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent glomerulonephritis/necrosis can be significantly improved.

The invention discloses an online sales recommendation system and method based on interest points, and the method comprises the steps: building a user database which is used for storing the account identification of a user, the authentication image of the user, an interest historical database and a shopping database, and when an offline shop detects that a certain user enters, carrying out the verification of the user, comparing the face image of the user with authentication images in a user database, and if the similarity between a certain authentication image in the user database and the face image of the user is greater than a similarity threshold, setting the user as a tracking user; acquiring a video image of the tracking user from entering the offline store to leaving the offline store as an analysis image, and analyzing the analysis image; when a certain user logs in an online client, the identification type of the account identification of the user is obtained, and a recommendation mode is determined according to the identification type.